Michael Snyder, Ph.D.

Recent technological advances as well as longitudinal monitoring not only have the potential to improve the treatment of disease (Precision Medicine) but also empower people to stay healthy (Precision Health). Precision health relies on the ability to detect early preclinical states, predict disease risks at an individual level and initiate preventive strategies. The main goal of this prospective cohort study was to quantify the impact of personalized longitudinal big data on human health. In this context, we enrolled 107 participants that underwent longitudinal integrative Personalized Omics Profiling (iPOP) for up to 8 years (median 2.5 years). Deep molecular profiling was performed quarterly over the study period and included standard clinical, enhanced (i.e.not part of standard clinical care) and emerging (i.e.used for exploratory purposes and mechanistic discoveries) tests. Emerging technologies included genomics, immunomics, transcriptomics, proteomics metabolomics and microbiomics. We discovered at least 45 actionable major health findings spanning various areas including metabolic, cardiovascular and oncology. In addition, we show that the majority of participants made diet and exercise changes due to study participation with the objective of improving their health. We also highlight emerging pathways relevant to diabetes and cardiovascular disease by evaluating the associations between multiomics measurements and standard clinical measures. Altogether, we conclude that deep longitudinal profiling using enhanced and emerging technologies can lead to actionable health discoveries and provide important information relevant for precision health.

CME Disclosure: Personalis, In9C, SensOmics: CoFounder & Advisor, Consulting Payments; Qbio and JaOnuary, Inc: CoFounder & Advisor, Stockholder